Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Entry into a Material Definitive Agreement
15 Apr 24
10-K
2023 FY
Annual report
27 Mar 24
8-K
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
27 Mar 24
S-8
Registration of securities for employees
23 Jan 24
8-K
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
8 Jan 24
8-A12B/A
Registration of securities on exchange (amended)
18 Dec 23
6-K
Current report (foreign)
18 Dec 23
6-K
Current report (foreign)
29 Nov 23
6-K
Current report (foreign)
16 Nov 23
6-K
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
23 Oct 23
6-K
Current report (foreign)
17 Oct 23
6-K
Current report (foreign)
20 Sep 23
6-K
Current report (foreign)
7 Sep 23
6-K
Ultragenyx Announces First Patients Dosed in Phase 3 Program
6 Jul 23
6-K
Current report (foreign)
30 Jun 23
6-K
Current report (foreign)
7 Jun 23
6-K
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
5 Jun 23
6-K
Current report (foreign)
22 May 23
6-K
Current report (foreign)
8 May 23
6-K
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5 May 23
6-K
Current report (foreign)
27 Apr 23
6-K
Current report (foreign)
12 Apr 23
20-F
2022 FY
Annual report (foreign)
28 Mar 23
6-K
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
28 Mar 23
6-K
Current report (foreign)
21 Mar 23
S-8
Registration of securities for employees
24 Jan 23
6-K
Current report (foreign)
10 Nov 22
6-K
Current report (foreign)
10 Nov 22
6-K
Current report (foreign)
2 Nov 22
6-K
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
2 Nov 22
6-K
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
28 Oct 22
6-K
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
21 Oct 22
6-K
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
18 Oct 22
6-K
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
17 Oct 22
6-K
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
3 Oct 22
6-K
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by
26 Sep 22
6-K
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
12 Sep 22
6-K
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
31 Aug 22
Latest ownership filings
SC 13D/A
Rubric Capital Management LP
16 Apr 24
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G/A
Rock Springs Capital Management LP
14 Feb 24
SC 13G
MANGROVE PARTNERS IM, LLC
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
4
Anders Ekblom
9 Feb 24
4
Pierre Jacquet
9 Feb 24
4
Marc J Yoskowitz
9 Feb 24
4
DEEPIKA PAKIANATHAN
9 Feb 24
4
MICHAEL S WYZGA
9 Feb 24
4
Daniel Shames
9 Feb 24
4
Annalisa Jenkins
9 Feb 24
4
Jeremy Bender
9 Feb 24
SC 13G/A
Soleus Private Equity Fund III, L.P.
6 Feb 24
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
5 Feb 24
4
Charles Sermon
26 Jan 24
4
Denise Scots-Knight
26 Jan 24
4
Alexandra Hughes-Wilson
26 Jan 24
4
John A. Lewicki
26 Jan 24
4
Christine Ann Fox
26 Jan 24
3
Anders Ekblom
2 Jan 24
3
Charles Sermon
2 Jan 24
3
Daniel Shames
2 Jan 24
3
Alexandra Hughes-Wilson
2 Jan 24
3
DEEPIKA PAKIANATHAN
2 Jan 24
3
Chrisitne Ann Fox
2 Jan 24
3
Annalisa Jenkins
2 Jan 24
3
John A. Lewicki
2 Jan 24
3
Denise Scots-Knight
2 Jan 24
3
MICHAEL S WYZGA
2 Jan 24
3
Pierre Jacquet
2 Jan 24
3
Marc J Yoskowitz
2 Jan 24
3
Justin Hunter Roberts
2 Jan 24
3
Jeremy Bender
2 Jan 24
3
David Efraim Rosen
2 Jan 24
SC 13D/A
Rubric Capital Management LP
20 Nov 23
SC 13D/A
Rubric Capital Management LP
15 Nov 23
SC 13D/A
Rubric Capital Management LP
13 Nov 23
SC 13D/A
Rubric Capital Management LP
8 Nov 23